Fig. 4From: Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi ArabiaBootstrap distribution of cost-effectiveness for natalizumab versus rituximabBack to article page